Drug profile · INN
trametinib
MEKINIST
trametinib (MEKINIST) is a dual specificity mitogen-activated protein kinase kinase; mek1/2 inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Drug details — trametinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
trametinib (MEKINIST) is a dual specificity mitogen-activated protein kinase kinase; mek1/2 inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
Primary target: Dual specificity mitogen-activated protein kinase kinase; MEK1/2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is trametinib?
trametinib (MEKINIST) is a dual specificity mitogen-activated protein kinase kinase; mek1/2 inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for trametinib?
MEKINIST is a marketed brand name for trametinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trametinib?
trametinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.